advanced search

Cardiometabolic Treatments, Rare Diseases, Variable Dosing, and Quanta

VIDEO

Bart Burgess discusses some of the key areas for innovation in the industry, such as rare diseases and moving away from variable dosing solutions, and introduces Quanta – SHL’s latest product offering.

Bart Burgess of SHL Medical spoke to us at Pharmapack 2026, offering his take on the trends currently redefining the pharmaceutical landscape, from the rise of cardiometabolic treatments to the urgent need for better rare disease solutions. He also highlights Quanta, SHL’s new device solution launched at Pharmapack 2026.

Previous article

Automated Testing to Decrease Time-To-Market

Next article

Sustainable Packaging and Patient-Centric Design

You may also like reading...

INTERVIEW
INTERVIEW with Dora Rio, Head of Sustainability, SHL Medical
Dora Rio discusses various aspects of SHL's approach to sustainability, including how it interacts with other players up and down the value chain, whether reusable or single-use devices are more sustainable and how SHL addresses sustainability concerns beyond CO2.
VIDEO
Automated Testing to Decrease Time-To-Market
Landon Goldfarb highlights the advantages conferred by Instron's Cobot automated testing system at both the design verification and production stages of autoinjector development.
INDUSTRIALISATION
AN AUTOINJECTOR REVOLUTION: ADVANCED SIMULATION TECHNOLOGIES ENHANCING GLOBAL MANUFACTURING NETWORKS
Edwin Hendrawan, Yi-Chi Lu and Christian Walter set out how SHL is building simulation capabilities, and describe how simulation will propel the business forward on every level, from individual shop floors to overall global expansion planning, in order to be able to meet the growing and increasingly complex demands from both pharma customers and patients.
Top